Read this first
This is plain-language harm-reduction information, not medical advice. Peptides discussed here are research compounds; most are not approved for human use. People will use them either way — we would rather they have the facts.
What it is
Survodutide is another GLP-1 + glucagon dual agonist, developed by Boehringer Ingelheim in partnership with Zealand Pharma. Phase II data shows ~19% weight loss at 46 weeks and impressive reduction in liver fat (MASH/NAFLD).
Still in trials as of 2026.
History
Developed by Boehringer Ingelheim / Zealand Pharma. Phase II results 2023; Phase III ongoing.
How it works
GLP-1 + glucagon dual agonism. Glucagon component appears to drive notable liver fat reduction in addition to weight effects.
Dosage
- Starting: 0.3 mg once weekly.
- Titration to 4–6 mg weekly over 12–16 weeks.
How it is taken
- Subcutaneous injection.
How to reconstitute
- 10 mg vial with 2 ml BAC water = 5 mg/ml. 3 mg = 60 units.
How it should arrive
White powder, sealed vial.
How it should look once reconstituted
Clear colourless solution.
What to expect, and when
- Appetite suppression: within days.
- Weight loss: ~19% at 46 weeks at top dose.
- Liver fat reduction: 12–24 weeks for measurable change.
Side effects
- Standard GLP-1 GI side effects.
- Mild heart rate increase.
Risks
- Pancreatitis.
- Limited long-term safety data.
Potential gains
- Strong weight loss.
- Best-in-class liver fat reduction among the dual agonists.
Other useful information
Of particular interest for people with fatty liver disease alongside obesity.
Looking for a goal-based recommendation?
Try the Find your goal tool — answer five short questions and get peptides matched to what you actually want.